Celldex Therapeutics, Inc. (CLDX) Ownership
CLDX ownership summary
as of October 17, 2026- Institutions
- 109.9% of shares outstanding
- Insiders
- 0.27% of shares outstanding
- Shares outstanding
- 78.5M
- Float
- 73.0M shares available to trade
- Short interest
- 16.63% 11.0M shares short
- Days to cover
- 6.00 short interest up 22.9% vs prior month
- Institutions 109.93%
- Insiders 0.27%
CLDX top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Wellington Management Company LLP | 12.16% | 9.5M | $262.7M | +983,195 (+11.5%) | June 30, 2026 |
| 2 | BlackRock Inc | 8.92% | 7.0M | $192.8M | +1.6M (+30.4%) | June 30, 2026 |
| 3 | Kynam Capital Management, LP | 6.78% | 5.3M | $146.5M | −517,659 (−8.9%) | June 30, 2026 |
| 4 | T. Rowe Price Associates, Inc. | 5.97% | 4.7M | $129.0M | +2.6M (+124.6%) | June 30, 2026 |
| 5 | State Street Corp | 4.97% | 3.9M | $107.4M | +1.1M (+39.1%) | June 30, 2026 |
| 6 | FMR Inc | 4.74% | 3.7M | $102.5M | −26,160 (−0.7%) | June 30, 2026 |
| 7 | Vanguard Capital Management, LLC | 4.41% | 3.5M | $95.4M | +503,936 (+17.0%) | June 30, 2026 |
| 8 | Deep Track Capital, LP | 3.74% | 2.9M | $80.9M | +1.7M (+128.9%) | June 30, 2026 |
| 9 | Logos Global Management LP | 2.68% | 2.1M | $57.8M | +1.6M (+366.7%) | June 30, 2026 |
| 10 | Geode Capital Management, LLC | 2.58% | 2.0M | $55.7M | +334,152 (+19.8%) | June 30, 2026 |
| 11 | Eversept Partners, LP | 2.28% | 1.8M | $49.2M | −2,075 (−0.1%) | June 30, 2026 |
| 12 | The Goldman Sachs Group Inc | 2.06% | 1.6M | $44.5M | +626,927 (+63.4%) | June 30, 2026 |
| 13 | Assenagon Asset Management SA | 2.01% | 1.6M | $43.4M | +1.4M (+976.5%) | June 30, 2026 |
| 14 | COMMODORE CAPITAL LP | 1.72% | 1.4M | $37.2M | −1.3M (−49.9%) | June 30, 2026 |
| 15 | Bellevue Group AG | 1.53% | 1.2M | $33.0M | — | June 30, 2026 |
| 16 | Baker Bros Advisors LP | 1.51% | 1.2M | $32.6M | +517,241 (+77.7%) | June 30, 2026 |
| 17 | Millennium Management LLC | 1.49% | 1.2M | $32.2M | −82,745 (−6.6%) | June 30, 2026 |
| 18 | Dimensional Fund Advisors, Inc. | 1.37% | 1.1M | $29.6M | +14,451 (+1.4%) | June 30, 2026 |
| 19 | American Century Companies Inc | 1.33% | 1.0M | $28.7M | +186,085 (+21.7%) | June 30, 2026 |
| 20 | Eventide Asset Management, LLC | 1.32% | 1.0M | $28.5M | — | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 13.2M shares and 5 cut 2.0M.
CLDX top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard Health Care Inv | 5.45% | 4.3M | $117.8M | — | June 30, 2026 |
| 2 | Vanguard MStar Total Stk Mkt Idx Invest | 3.18% | 2.5M | $68.7M | −5,169 (−0.2%) | August 31, 2026 |
| 3 | iShares Russell 2000 ETF | 2.57% | 2.0M | $55.6M | −23,296 (−1.1%) | September 30, 2026 |
| 4 | State Street® SPDR® S&P® Biotech ETF | 2.06% | 1.6M | $44.4M | −30,850 (−1.9%) | September 30, 2026 |
| 5 | Vanguard Explorer Inv | 1.84% | 1.4M | $39.9M | +390,068 (+36.9%) | June 30, 2026 |
| 6 | T. Rowe Price New Horizons | 1.53% | 1.2M | $33.0M | −49,052 (−3.9%) | August 31, 2026 |
| 7 | Eventide Healthcare & Life Sciences I | 1.32% | 1.0M | $28.5M | — | June 30, 2026 |
| 8 | T. Rowe Price Integrated US Sm Gr Eq | 1.24% | 971K | $26.7M | — | August 31, 2026 |
| 9 | Fidelity Small Cap Index | 1.09% | 855K | $23.5M | +6,992 (+0.8%) | July 31, 2026 |
| 10 | American Century Small Cap Growth Inv | 1.01% | 793K | $21.8M | +245,219 (+44.7%) | June 30, 2026 |
| 11 | Fidelity Select Biotechnology | 0.99% | 778K | $21.4M | +364,000 (+87.8%) | August 31, 2026 |
| 12 | Fidelity Advisor Biotechnology I | 0.83% | 651K | $17.9M | +138,600 (+27.1%) | August 31, 2026 |
| 13 | Pictet-Biotech P USD | 0.77% | 601K | $16.5M | −2,435 (−0.4%) | June 30, 2026 |
| 14 | Strategic Advisers Fidelity US TtlStk | 0.76% | 596K | $16.4M | +35,281 (+6.3%) | August 31, 2026 |
| 15 | iShares Russell 2000 Growth ETF | 0.75% | 592K | $16.3M | −750 (−0.1%) | September 30, 2026 |
| 16 | Fidelity Small Cap Growth | 0.60% | 474K | $13.0M | — | July 31, 2026 |
| 17 | Vanguard Russell 2000 ETF | 0.57% | 449K | $12.4M | +10,705 (+2.4%) | August 31, 2026 |
| 18 | Fidelity Small Cap Discovery | 0.55% | 434K | $11.9M | +25,200 (+6.2%) | July 31, 2026 |
| 19 | T. Rowe Price Health Sciences | 0.55% | 432K | $11.9M | −62,200 (−12.6%) | August 31, 2026 |
| 20 | Schwab US Small-Cap ETF™ | 0.53% | 413K | $11.4M | +279 (+0.1%) | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
CLDX insider transactions
latest 1| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-13 | Richard M Wright | Sell | $24.00 | 49,298 | $1.2M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
CLDX shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns CLDX
Institutional investors own 109.9% of Celldex Therapeutics's shares and insiders 0.27%. The largest holder is Wellington Management Company LLP with 12.16% of the shares (9.5M), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 5 reduced their stake in the latest filings. Short interest is 16.63% of the float, or 6.00 days of average trading volume. The share count rose 1,013.8% since 2014.
Related: CLDX analyst forecast, CLDX key metrics. See the CLDX stock overview for the latest quote and news.
CLDX ownership FAQ
Who owns the most Celldex Therapeutics stock?
The largest shareholders of Celldex Therapeutics are Wellington Management Company LLP (12.16%), BlackRock Inc (8.92%), Kynam Capital Management, LP (6.78%), T. Rowe Price Associates, Inc. (5.97%), State Street Corp (4.97%).
What percentage of Celldex Therapeutics is owned by institutions?
Institutions hold 109.9% of Celldex Therapeutics's shares outstanding; insiders hold 0.27%.
Which funds own Celldex Therapeutics?
The largest fund holders of Celldex Therapeutics are Vanguard Health Care Inv (5.45%), Vanguard MStar Total Stk Mkt Idx Invest (3.18%), iShares Russell 2000 ETF (2.57%), State Street® SPDR® S&P® Biotech ETF (2.06%), Vanguard Explorer Inv (1.84%).
What is Celldex Therapeutics's short interest?
11.0M shares of Celldex Therapeutics were sold short, 16.63% of the float; at the average daily volume it would take 6.00 days to cover.
Are insiders buying or selling Celldex Therapeutics?
Of the latest 1 reported insider transactions in Celldex Therapeutics (since November 13, 2025), 0 were purchases and 1 were sales.
How many shares of Celldex Therapeutics are outstanding?
Celldex Therapeutics has 78.5M shares outstanding, of which 73.0M are in the public float.